Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916624 | 0.93 | PDE7A (0.40) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL915352 | 0.93 | PDE7A (0.43) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL916539 | 0.91 | MAPK1 (0.44) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL917614 | 0.88 | SMN1; SMN2 (0.39) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL916549 | 0.87 | RECQL (0.48) | KMT2AMEN1ALDH1A1HTTMAPT | |
| SCHEMBL916492 | 0.85 | PDE7A (0.39) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL915774 | 0.85 | KMT2A (0.42) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL916281 | 0.85 | PDE7A (0.39) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL916099 | 0.84 | PDE7A (0.37) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL916197 | 0.84 | PDE7A (0.37) | KMT2AMEN1ALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | KMT2A 3473/4885MEN1 2248/4885POLB 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.